Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 (nintedanib) in idiopathic pulmonary fibrosis
CTR20131477Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Nintedanib 150 mg with Placebo (2 arms). Primary endpoint: Annual rate of decline in FVC (mL) over 52 weeks. Started Sep 2014; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20131477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131477.